Muhammad Waseem, MD
Internal Medicine · Hagerstown, MDNPI 1184665143
Payments from drug & device makers
Across 118 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$232
- GSK$174
- Sunovion Pharmaceuticals Inc.$165
- Johnson & Johnson$153
- Novartis$148
- Abbott$147
- plus $787 from 21 others
What the payments were for
- Speaking & faculty fees$442%
- Food & beverage$1,74897%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $232 |
| GSK | 5 | $174 |
| Sunovion Pharmaceuticals Inc. | 10 | $165 |
| Johnson & Johnson | 17 | $153 |
| Novartis | 11 | $148 |
| Abbott | 8 | $147 |
| Pfizer | 8 | $140 |
| Lilly USA, LLC | 7 | $125 |
| Eisai Inc. | 3 | $59 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Lifescan, Inc. | 2 | $45 |
| Acorda Therapeutics, Inc | 2 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| AstraZeneca | 3 | $37 |
| Boehringer Ingelheim | 2 | $31 |
| Amgen | 2 | $29 |
| Exact Sciences | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $21 |
| Medtronic | 1 | $17 |
| Bayer | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
How this compares
$1,807 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 541 | $234,556 |
| JardianceEmpagliflozin | 121 | $52,549 |
| XareltoRivaroxaban | 135 | $51,832 |
| JanuviaSitagliptin Phosphate | 69 | $35,529 |
| TrulicityDulaglutide | 54 | $33,723 |
| MounjaroTirzepatide | 24 | $30,268 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $21,358 |
| RexultiBrexpiprazole | 27 | $19,793 |
| LinzessLinaclotide | 32 | $18,046 |
| Spiriva RespimatTiotropium Bromide | 32 | $17,385 |
| AptiomEslicarbazepine Acetate | 12 | $15,739 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $15,521 |
| OzempicSemaglutide | 13 | $13,369 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $13,000 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 39 | $11,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $140 | $242,449566 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Synjardy | $31 | $87,346187 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $125 | $63,99178 claims |
| Johnson & JohnsonXarelto | $153 | $51,832135 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Anoro Ellipta | $174 | $46,339112 claims |
| AbbVieLinzess | $16 | $18,04632 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $165 | $15,73912 claims |
| Novo NordiskOzempic | $232 | $13,36913 claims |
| NovartisEntresto | $148 | $9,24126 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $5,10822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Hagerstown
- Mary HowellHagerstown$6.2M
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.